Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01469585 · ClinicalTrials.gov registry record · NA
Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases
A NA study of Breakthrough Bleeding, sponsored by University of Hawaii.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01469585 is a NA study of Breakthrough Bleeding that has completed, run by University of Hawaii. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01469585, a NA study of Breakthrough Bleeding, has completed, sponsored by University of Hawaii.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effects (good and bad) of subantimicrobial dose doxycycline on the irregular bleeding women experience when taking continuous oral contraceptive pills. This research is being done because currently, there is no effective treatment for this condition. Findings from this study could help to decrease the side effects of birth control pills and decrease unplanned pregnancies.
Conditions Studied
Interventions
- DRUG Doxycycline
Study Locations (1)
Hawaii
- Kapiolani Medical Center for Women and Children - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01469585
The ClinicalTrials.gov registry entry for NCT01469585 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breakthrough Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Doxycycline is the first listed.
NCT01469585 reports 1 study location spanning 1 distinct geographic area - top geographies include Hawaii.
Frequently Asked Questions
What is clinical trial NCT01469585 about?
NCT01469585 is a clinical study titled "Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases". The purpose of this study is to compare the effects (good and bad) of subantimicrobial dose doxycycline on the irregular bleeding women experience when taking continuous oral contraceptive pills. This research is being done because currently, there is no effective treatment for this condition. Findi...
What is the current status of trial NCT01469585?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2011-11. Estimated completion is 2012-05.
What conditions does trial NCT01469585 study?
This clinical trial studies the following conditions: Breakthrough Bleeding.
What interventions are being tested in trial NCT01469585?
The interventions under investigation include: Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01469585?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01469585 being conducted?
This trial has 1 study location across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breakthrough Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.